Stock listing
AVBP Stock Price, News, Filings & Events — Arrivent Biopharma, Inc.
Selected listing: AVBP · NASDAQ · USD · US
This page tracks Arrivent Biopharma, Inc.'s AVBP:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following AVBP:NASDAQ. AVBP:NASDAQ is the stock-level entry point for investors researching Arrivent Biopharma, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Arrivent Biopharma, Inc. is a public company traded under the ticker AVBP in the American market. The company has a market capitalization of approximately $1.55 billion. Arrivent focuses on developing innovative biopharmaceutical solutions to address unmet medical needs.

- Ticker
- AVBP:NASDAQ
- Asset type
- Stock
- Market cap
- $1.43B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Other
- Exchange
- NASDAQ
- Currency
- USD
Arrivent Biopharma, Inc. AVBP:NASDAQ stock context
This page tracks Arrivent Biopharma, Inc.'s AVBP:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following AVBP:NASDAQ. AVBP:NASDAQ is the stock-level entry point for investors researching Arrivent Biopharma, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Arrivent Biopharma, Inc. is a public company traded under the ticker AVBP in the American market. The company has a market capitalization of approximately $1.55 billion. Arrivent focuses on developing innovative biopharmaceutical solutions to address unmet medical needs.
Latest news from Arrivent Biopharma, Inc.
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
August 12, 2026
ArriVent BioPharma Reports First Quarter 2026 Financial Results
May 11, 2026
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial C...
May 7, 2026
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC...
March 17, 2026
ArriVent BioPharma Reports Full Year 2025 Financial Results
March 5, 2026
Research Arrivent Biopharma, Inc.
Arrivent Biopharma, Inc. investor report
Review AI stock analysis and investor report context for AVBP:NASDAQ.
Arrivent Biopharma, Inc. company profile
View the public company page for Arrivent Biopharma, Inc. on 6ix.
Arrivent Biopharma, Inc. news
Read company news and market updates connected to Arrivent Biopharma, Inc..
Arrivent Biopharma, Inc. investor events
Find investor webinars, events, and replay context for Arrivent Biopharma, Inc..